HNRNPD and breast carcinoma: Moreover, tocilizumab (the inhibitor of IL-6 receptor) can inhibit the cancer-promoting effect of CAFs in breast cancer by inhibiting the STAT3/AU-rich element RNA-binding protein 1 (AUF1) pathway [114].